Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial

Signe Kjeldgaard Jensen*, Trine Mølbæk Jensen, Nina Marie Birk, Lone Graff Stensballe, Christine Stabell Benn, Kristoffer Jarlov Jensen, Ole Pryds, Dorthe Lisbeth Jeppesen, Thomas Nørrelykke Nissen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Background: The Bacille Calmette-Guérin (BCG) vaccine against tuberculosis (TB) may have beneficial non-specific effects (NSEs) beyond the protection against TB. This may be related to modifications of the innate immune system. We investigated the effect of BCG at birth on differential white blood cell (WBC) count in healthy, Danish infants. Method: The Danish Calmette Study randomised newborns to BCG at birth (Danish strain 1331, Statens Serum Institut) or no intervention. A sub-group of infants had blood samples collected 4 days after randomisation (n = 161), and at age 3 months (n = 152) and 13 months (n = 300). We evaluated the effect of BCG on WBC differential count (total leucocytes, lymphocytes, monocytes, eosinophil, neutrophil and basophil granulocytes (109 cells/L)) measured in peripheral blood. Results: Overall, we found no effect of BCG on differential WBC counts at any time point. Conclusion: BCG at birth did not affect WBC count in our cohort of healthy, Danish infants.
Original languageEnglish
JournalVaccine
Volume38
Issue number11
Pages (from-to)2449-2455
ISSN0264-410X
DOIs
Publication statusPublished - 2020

Keywords

  • Bacillus Calmette-Guérin
  • Heterologous immunity
  • Infants
  • Non-specific effects
  • Trained innate immunity
  • Vaccination
  • White blood cell differential count

Cite this

Jensen, S. K., Jensen, T. M., Birk, N. M., Stensballe, L. G., Benn, C. S., Jensen, K. J., Pryds, O., Jeppesen, D. L., & Nissen, T. N. (2020). Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial. Vaccine, 38(11), 2449-2455. https://doi.org/10.1016/j.vaccine.2020.02.006